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Introduction
The precise mechanism by which fumonisin
B1 (FB1) induces increased apoptotic and
oncotic necrosis and ultimately tumors in
rodent liver and kidney is unclear. Several
biochemical modes of action have been pro-
posed. Two of these invoke disruption of
lipid metabolism as either the initial or a key
event in the cascade of molecular changes
leading to the diseases associated with expo-
sure to toxic concentrations of fumonisins.
Currently a great deal of correlative evidence
from in vivo studies supports the premise that
altered sphingolipid metabolism is closely
associated with the liver and kidney toxicity
observed in rodents and farm animals: 
• Equids: Free sphingoid bases increase in
serum, liver, and kidney, and more com-
plex sphingolipids decrease in liver and
kidney before indications of hepato-
toxicity (1,2).
• Pigs: Dose-dependent increase in free
sphingoid bases in serum and liver and
decreased complex sphingolipids in liver are
correlated with hepatotoxicity; the increase
in free sphingoid bases in liver, kidney, and
lung precedes the onset of hepatotoxicity
and pulmonary edema (3–6).
• Rats: Free sphingoid base concentration
in serum, urine, liver, or kidney and
decreased complex sphingolipids in liver
and kidney are correlated with the extent
and severity of the hepatotoxicity and/or
nephrotoxicity or other indicators of
cytotoxicity (7–12).
• Mice: Free sphingoid base concentration
in liver and kidney is correlated with
increased apoptosis and oncosis in liver
and kidney [(13–17) and Figure 1].
• Trout: Free sphingoid base concentration
in liver is correlated with promotion of
tumors in aﬂatoxin B1-initiated trout fed
FB1 (Figure 2).
Numerous studies also hypothesize
fumonisin-induced changes in key enzymes
involved in cell cycle regulation, differentia-
tion, and/or apoptosis as initial or secondary
sites of action:
Alterations in key enzymes or effectors of
cell cycle progression and apoptosis:
• Altered expression or activity of protein
kinase C, altered phorbol dibutyrate
binding (18,19) 
• Activation of the mitogen-activated
protein kinase (20)
• Inhibition of serine/threonine phos-
phatases (21)
• Altered expression of cyclins, cyclin-
dependent kinases, and dephosphoryla-
tion of the retinoblastoma protein (22,23)
• Overexpression of transforming growth
factor-β1 and c-myc in rat liver (24) 
• Apoptosis inhibitor and protease inhibitor
protection from apoptosis (25)
Alterations in processes often associated
with increased cellular/organ toxicity: 
• Increased tumor necrosis factor (TNF)-α
secretion in lipopolysaccharide-activated
macrophages (26) 
• Altered calcium homeostasis (27) 
• Alterations in antioxidants, increased lipid
peroxidation, alterations in saturation of
fatty acids and other lipid changes
(8,28–33)
• Stimulation of nitric oxide production
(34).
Many of these latter studies have been
conducted using cultured cells or other
in vitro systems. In some cases changes in
sphingolipids were measured; however, a
causal link was not established. This review
summarizes the evidence that supports dis-
rupted sphingolipid metabolism as a con-
tributing factor in fumonisin-induced diseases
and discusses how disruption of sphingolipid
metabolism can alter the rates of cell death
and proliferation and thus contribute to the
increased cancer risk in the liver and kidney
of rodents.
Disruption of Sphingolipid
Metabolism 
The pathway of de novo sphingolipid biosyn-
thesis begins with the condensation of serine
with palmitoyl-CoA and proceeds rapidly to
the biosynthesis of ceramide (CER) and more
complex sphingolipids (Figure 3A). The
turnover of more complex sphingolipids results
in the production of CER, sphingosine, and
sphingosine 1-phosphate (Figure 3A), which
are either proven or suspected lipid-signaling
molecules [for review see Hannun and Luberto
(35) and Spiegel (36)]. Fumonisins potently
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inhibit the enzyme CER synthase (Figure 3B),
which catalyzes the acylation of sphinganine
and reacylation of sphingosine (38–40). CER
synthase recognizes both the amino group
(sphingoid-binding domain) and the tricar-
ballylic acid side chains (fatty acyl CoA
domain) of fumonisin B1 (41,42). The
reduced effectiveness of the hydrolyzed deriva-
tives of the fumonisin B (FB) series (40,43)
and the inability of pure N-acetylated FB1 to
inhibit CER synthase in cultured cells (43),
support this hypothesis. There is a conﬂicting
report about the ability of N-acetylated FB1 to
inhibit CER synthase (44). Differing from the
results of Norred et al. (43), van der
Westhuizen et al. (44) reported that in primary
rat hepatocytes, N-acetylated FB1 was an
inhibitor of CER synthase. A possible explana-
tion for this discrepancy is that N-acetylated
FB1 can decompose to its O-acetylated isomer
and possibly to FB1 during storage (45).
Interestingly, aminopentol 1, but not FB1, can
be a substrate for CER synthase and the
N-palmitoyl-aminopentol 1 may also inhibit
CER synthase in cultured cells (46). 
The binding of fumonisin to the catalytic
site of CER synthase is the ﬁrst event in the
process referred to as “disruption of sphin-
golipid metabolism.” A common misconcep-
tion is that inhibition of CER synthase and
elevation of free sphingoid bases occur con-
currently and are synonymous. The term
“fumonisin disruption of sphingolipid metab-
olism” encompasses all the changes that can
occur in the biosynthetic rates and intracellu-
lar concentrations of the intermediates and
end products within both the de novo sphin-
golipid pathway and branch pathways (such
as those leading to changes in biosynthesis of
glycerophospholipids and neutral lipids). The
biochemical consequences of fumonisin dis-
ruption of sphingolipid metabolism (Figure
4) that are most likely to lead to altered cell
regulation are: altered CER biosynthesis [for
review see Hannun and Luberto (35) and
Kolsnick and Krönke (37)], increased intra-
cellular concentration of free sphingoid bases
and their 1-phosphates [for review see Spiegel
(36) and Merrill et al. (47)], and alterations
in the cellular concentration of specific
glycosphingolipids [for review see Ledeen
et al. (48)]. 
Increased Free Sphingoid Bases
The complete inhibition of CER synthase by
fumonisins causes the intracellular sphinganine
concentration to increase rapidly (38,39).
However, before this can occur, the capacity of
sphingosine kinase to degrade free sphinganine
must be exceeded. It is possible that partial
inhibition of CER synthase could increase the
rate of sphingoid base 1-phosphate biosynthe-
sis without any apparent increase in the free
sphinganine concentration. Free sphingosine
concentration may also increase through
fumonisin inhibition of reacylation of sphingo-
sine derived from sphingolipid turnover or
dietary sources/growth medium (Figure 3B).
Nonetheless, when toxicity is evident, approxi-
mately 95% of the increase in free sphingoid
bases in tissues and cultured cells is caused by
the increase in free sphinganine (39) or
sphingoid bases other than sphingosine (49). 
In cultured cells the increase in free
sphinganine and the decreased incorporation
of radiolabeled serine or fatty acids into com-
plex sphingolipids can be detected within a
few hours after adding fumonisin (38,39,40).
In mice dosed once subcutaneously with FB1,
the free sphinganine concentration in liver
and kidney was signiﬁcantly increased within
2 hr of dosing and in liver returned to the
control concentration after 24 hr (50).
Figure 1. An example of the close correlation between fumonisin-induced disruption of sphingolipid metabolism and
onset of toxicity in vivo in six strains of mice (14–17). The correlation between free sphinganine (nanomoles per gram
fresh weight) in liver and (A) histopathologic ﬁndings (liver scores from hematoxylin- and eosin–stained sections) in
livers, and (B) liver enzymes (ALT= alanine aminotransferase, units/liter) in serum from six (3–4 of each) different
types of male mice dosed subcutaneously with 2.25 mg FB1/kg body weight/day for 5 days. FVB, FVB mdr1a/b,
C57BL/6, C57BL/6NTacfBR-[Tg]TNF mice were obtained from Taconic Farms, Germantown, NY; and C57BL/6J and
C57Bl6-Tnfrsf 1btm1Mwm were obtained from Jackson Laboratories, Bar Harbor, ME. Livers from concurrent controls
(n = 21) and fumonisin-treated mice (n = 22) were examined without regard to identity and subjectively placed in one
of three categories: a) normal or least affected—morphologically unremarkable livers containing no or only a few
scattered apoptotic hepatocytes (“least” affected were normal-appearing FB1-treated mice after all readings were
complete); and b) “minimal” or c) “obvious,” depending on the amount of apoptosis, mitosis, cytoplasmic vacuolation,
cytomegaly, differences in nucleus to cytoplasmic ratio, and necrosis found. All control livers were scored as “least”
and are grouped together for comparison to the fumonsin-treated livers. Inset in (A) are the total thiobarbituric
acid–reactive substances (TBARS) in nanograms malondialdehyde equivalents/20 mg fresh weight for the same liver
score groups (control, least, minimal, obvious). The free sphinganine was analyzed as described in Riley et al. (83)
and TBARS as per Abel and Gelderblom (33). Additional details of the dosing regimen, criteria for liver scores, and
rationale for selecting mouse strains have been described elsewhere (14–17). Care and treatment of animals were
approved by the University of Georgia Animal Use Committee.
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Figure 2. An example of the close correlation between
fumonisin-induced disruption of sphingolipid metabolism
and cancer promotion in vivo in trout (90). The correla-
tion between free sphinganine (nanomoles per gram
fresh liver weight) tumor incidence in liver from trout fry
initiated by immersion in a bath of 100 ng/L of aﬂatoxin
B1 is presented. After a 1-month outgrowth period fish
were fed 0, 5, 25, or 100 ppm FB1 for 42 weeks before
necropsy at 60 weeks. The free sphinganine values are
those in livers at 24 weeks (n = 3/dose group) and the
tumor incidence at 60 weeks. Methods for the diet for-
mulation, fumonisin analysis, and sphingolipid analysis
are given in Meredith et al. (91). Care and treatment of
animals were approved by the Oregon State University
Animal Use Committee.
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However, in kidney the free sphinganine
concentration remained signiﬁcantly elevated
after 48 hr (50) but returned to control levels
after about 96 hr (51). 
The half-life of the accumulated free
sphinganine inside LLC-PK1 renal epithelial
cells is much longer than the half-life of FB1
in cells (49), which suggests that either the
inhibition of sphinganine N-acyltransferase is
persistent, sphinganine metabolism is slow,
and/or sphinganine does not easily diffuse out
of cells. When the serine palmitoyltransferase
inhibitor produced by Isaria Sinclairii (ISP-I
=myriocin=thermozymozydin) is added to
fumonisin-treated renal cells, the free sphin-
ganine concentration returns rapidly to con-
trol concentrations (Figure 5), indicating that
the accumulation of free sphingoid bases in
renal cells is a consequence of the differences
in the kinetics of serine palmitoyltransferase
compared to those of the enzymes in the
degradative pathway [sphingosine (So-)
kinase and So-lyase]. Elevated free sphinga-
nine may also persist in kidney in vivo, given
that free sphinganine was detected in dead
cells collected from rat urine (7), free sphin-
ganine in rat urine remained elevated for
approximately 10 days after the rats were
taken off diets containing FB1 (55), and free
sphinganine remained elevated in mouse kid-
ney after it had returned to control levels in
the small intestines and liver (50,51). 
Proliferating renal cells accumulate much
higher concentrations of free sphingoid bases
than conﬂuent monolayers, and cytotoxicity is
most readily detected in rapidly proliferating
or growing cells (53,56). Increased concen-
tration of free sphinganine is also seen in the
livers of partially hepatectomized, fumonisin-
treated rats relative to the sham-operated
fumonisin-treated rat livers (57). This proba-
bly occurs because the activity of the rate limit-
ing enzyme, serine palmitoyltransferase, is
maturationally expressed and is much more
active in subconﬂuent, undifferentiated, meta-
bolically active cells and tissues. Because of the
slower turnover rate of more complex sphin-
golipids, free sphingoid base concentration
increases in fumonisin-exposed LLC-PK1 renal
epithelial cells and in liver and kidney in vivo
before the complex sphingolipid concentration
decreases (3,7,13,53). However, even though
the complex sphingolipid pool size may change
slowly, the rate of de novo sphingolipid biosyn-
thesis is directly related to the extent of inhibi-
tion of CER synthase. Thus, cellular processes
dependent on glucosylceramide biosynthesis
could be affected with no apparent decrease in
glycosphingolipid pool size. 
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Figure 3. (A) The pathway of de novo sphingolipid biosynthesis and turnover in a mammalian cell. Abbreviations: A-SMase, acidic sphingomyelinase; DHC-desaturase, dihydro-
ceramide desaturase; FB, ceramide synthase inhibitor; SPTase, serine palmitoyltransferase; SPTI, serine palmitoyltransferase inhibitor. Large solid arrows indicate the enzymatic
steps leading to biosynthesis of CER, a known effector of cell death [for review see Hannun and Luberto (35)], and large broken arrows show the enzymatic steps leading to the
production of SPP, an effector of cell survival or “life” [for review see Spiegel (36)]. Free sphinganine is an intermediate and not an end product in the sphingolipid biosynthetic
pathway. Thus, in cells that have not been exposed to fumonisin, the free sphinganine concentration is low (< 0.5–3 nmol/g wet weight) and therefore not toxic. Free sphingosine
concentration is also low; however, it is not an intermediate in the de novo pathway in mammalian cells but is formed as a consequence of sphingolipid turnover. Also shown is
the proposed role of mitochondrial perturbations triggering a redirection of palmitate from beta-oxidation into the de novo pathway, producing increased biosynthesis of CER
under conditions of oxidative stress [for review see Kolesnick and Krönke (37)]. (B) The sites of action of SPTIs such as ISP-I, and CER synthase inhibitors such as fumonisins
(B and C series and their aminopentols). Also shown is the consequence of inhibition of CER synthase under conditions that allow the accumulation of toxic levels (> 12–150
nmol/g wet weight) of free sphinganine (Death). The block on the CER synthase responsible for its reacylation produces an increase in free sphingosine and possibly SPP.
However, sphinganine 1-phosphate does not exert a marked cytoprotective effect but binds to and signals via the G protein–coupled receptor encoded by endothelial differentia-
tion gene 1 (36). Also shown in (A) is the generation of CER by ligand-induced sphingomyelin hydrolysis [for review see Hannun and Luberto (35)]. 
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Figure 4. The biochemical consequences of fumonisin
inhibition of CER. GSL, glycosphingolipid. Arrows indi-
cate the direction of the change in either the concentra-
tion of the biochemical pool or the rate of biosynthesis
of the intermediate or end product.
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Figure 5. An example of how the activity of enzymes in
the de novo and turnover pathways can influence the
accumulation of sphingoid bases (picomoles per mil-
ligram protein) and their metabolism (52). Abbreviations:
So, sphingosine; Sa, sphinganine. Inhibition of SPTase
rapidly returns free sphinganine to control concentra-
tions, indicating that the rate of sphinganine biosynthe-
sis exceeds the rate of sphinganine metabolism in
LLC-PK1 renal epithelial cells. Confluent LLC-PK1 renal
epithelial cells grown in 24-well culture plates
(2 cm2/well) were exposed to fumonisin B1 (25 µM) for
48 hr. Group A: control-treated (not exposed to fumon-
isin B1) at 48 hr. Group B: fumonisin B1-treated for 48 hr.
Group C: fumonisin B1-treated for 48 hr; then culture
medium was replaced with medium without fumonisin
B1 and incubated for an additional 6 hr. Group D: fumon-
isin B1-treated for 48 hr; then culture medium was
replaced with medium without fumonisin B1 but with
150 nM ISP-I and incubated for an additional 6 hr. Free
sphinganine was analyzed and LLC-PK1 renal epithelial
cells were handled as described in Yoo et al. (53). ISP-I
was isolated and purified as described in Riley and
Plattner (54). 
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Fumonisin exposure also leads to
imbalances in phosphoglycerolipid and fatty
acid metabolism in vitro (8,38,40). In fumon-
isin-treated hepatocytes a portion of the accu-
mulated sphinganine is metabolized to
sphinganine 1-phosphate (SPP) and then
cleaved into a fatty aldehyde and ethano-
lamine phosphate (40), both of which can be
redirected into other biosynthetic pathways.
It has been estimated that in fumonisin-
treated cells, about one-third of the ethanol-
amine in phosphatidylethanolamine is
derived from long-chain sphingoid base
catabolism (58,59). The concentration of
phosphatidylethanolamine also increases in the
liver of rats fed fumonisins (8). The ability of
cells to rapidly metabolize bioactive sphingoid
bases into less bioactive products or into prod-
ucts such as SPP may protect cells from the
toxicities associated with either elevated free
sphingoid bases or CER (36). In mammalian
cells, as in yeast, the balance between the
endogenous CER and SPP concentration
determines whether a cell dies or survives (36).
This balance is maintained by the relative activ-
ity of various key enzymes in the de novo and
sphingolipid turnover pathways (Figure 3A). 
Although in vivo studies have found a
close correlation between disrupted sphin-
golipid metabolism and the onset and pro-
gression of liver and kidney toxicity, no
definitive study in vivo has shown that dis-
rupted sphingolipid metabolism is the cause
of the increased apoptosis observed in liver
and kidney in vivo. Several in vitro studies
with cultured cells have shown that reduction
of free sphinganine with ISP-Is completely or
partially reverses the effects of FB1 on cell
growth, differentiation, and/or cell death.
Free sphingoid bases induce cell death and
altered cell growth: 
• Sphingoid bases are growth inhibitory,
cytotoxic, and induce apoptosis (53,
60–66).
• Sphingoid bases or their metabolites can
be growth stimulating [for review see
Spiegel (36)].
Fumonisin effects on cell growth and cell
death are reversed by serine palmitoyl-
transferase inhibitors (SPTI) of sphinganine
accumulation: 
• SPTI reverses FB inhibition of cell growth
and increased cell death and apoptosis in
pig renal cells, human colonic cells, pri-
mary human keratinocytes (39,56,65,67). 
• SPTI reverses FB-induced stimulation of
[3H]thymidine incorporation in Swiss
3T3 cells (68).
Other fumonisin effects closely correlated
with elevated free sphingoid bases: 
• Endothelial cell permeability (69)
• Protein kinase C modulation (70).
Other studies demonstrate that supple-
mentation of growth medium with CER or
more complex sphingolipids also can
completely or partially reverse the effects of
FB1 on cell growth, differentiation, and/or
cell death:
• Decreased axonal growth, morphologic
changes in ﬁbroblasts, and altered growth
factor stimulation of axonal growth are
reversed by addition of CER or gangliosides
(71–73)
• Cell substratum adhesion (74)
• Glycosylphophatidylinositol-anchored pro-
tein functions such as the folate receptor
(75,76)
• Assembly and disassembly of cytoskeletal
proteins responsible for lipid transport and
maintenance of the subcellular architecture
(77)
• Biosynthesis and retrograde transport of
attachment sites for microbial pathogens
and toxins and protein transport to the
plasma membrane (78,79)
• Multidrug resistance in certain cancer
cells (80)
• Glucosylceramide synthesis is required for
axonal growth and chick embryo develop-
ment (81,82). 
Supporting the notion that fumonisin-
induced alterations in sphingolipid metabo-
lism can lead to increased apoptosis and
altered cell proliferation is the fact that sphin-
golipids and their metabolites are known reg-
ulators of cell growth, differentiation,
apoptosis, necrosis, and immune response: 
Sphingoid bases and their metabolites [for
review see Spiegel (36) and Merrill et al.
(47,84)]:
• Inhibition of protein kinase C, activation
of proteases
• Activation of phospholipase D/inhibition
of phosphatidic acid phosphatase
• Activation of the epidermal growth factor
receptor kinase (probably via mitogen-
activated protein kinase) 
• Control of intracellular calcium (seem-
ingly via SPP)
• Control of plasma membrane potassium
permeability in myocytes
• Inhibition of DNA primase and increases
in transcription factor activator protein-1
• Ligand (SPP) for the endothelial differen-
tiation gene 1 receptor. 
CER [for review see Hannun and Luberto
(35) and Kolesnick and Krönke (37):
• Second messenger in cytokine signal
transduction
• Activity of protein kinases, phosphatases,
and mitogen-activated protein kinases
• Activity of phospholipase D, cytosolic
phospholipase A2
• Transcription factor nuclear factor kappa B
• CPP32-like caspases.
More complex sphingolipids [for review
see Futerman (85), Yates and Rampersaud
(86), and Radin (87)]: 
• Binding of cytoskeletal proteins 
• Participation in cell–cell communication
and cell–substratum interactions
• Receptor-mediated transport and sorting
by lipid rafts 
• Modulation of growth factor receptors.
Also, mutants defective in sphingolipid
biosynthesis are growth suppressed (88).
Because of the large number of regulatory
processes known to be affected by sphin-
golipids and the crosstalk between sphin-
golipid and glycerophospholipid signaling
pathways, unraveling the downstream mecha-
nisms by which fumonisin-induced sphin-
golipid alterations cause tissue damage will be
extremely challenging. 
In Sprague-Dawley and Fischer 344 rats,
New Zealand white rabbits, and BALB/c and
other mouse strains, disruption of sphin-
golipid metabolism (as evidenced by increased
free sphinganine concentration) occurs at
fumonisin dosages that do not cause morpho-
logic evidence of injury (7,8,10–13,89).
Where liver pathology is observed, there is a
close correlation between the incidence and
severity of the pathology and the increase in
free sphinganine indicative of disrupted
sphingolipid metabolism (for example, see
Figures 1 and 2). In mice, this occurs with
no apparent increase in lipid peroxidation
(Figure 1A, inset). In rats (92) and rabbits
(93), the kidney is extremely sensitive to
fumonisin-induced nephrotoxicity. Voss et
al. (92) found the dietary no-observed-effect
level (NOEL) for nephrosis in male Fischer
344 rats was 3 parts per million (ppm),
whereas increased renal free sphinganine has
been found in male Sprague-Dawley rats fed
AIN-76 diets containing 1 ppm FB1 (55). In
male RIVM:WU rats, liver free sphinganine
was significantly elevated at > 0.19 < 0.75
mg FB1/kg body weight (equivalent to 1.9
and 7.5 ppm dietary FB1). The increase
occurred in the absence of any evidence of
hepatosis (11). The low-observed-effect level
for tubular cell death and significant
increases in kidney free sphinganine was <
0.19 mg FB1/kg body weight, which was
equivalent to < 1.9 ppm in feed (11). 
In Sprague-Dawley rat urine, free sphin-
ganine accumulation in dead cells closely
reflected the changes in sphingolipids and
nephrotoxicity that occurred in the kidney
(7). The results of the recently completed
U.S. Food and Drug Administration long-
term feeding study in rats confirms these
ﬁndings (12). Feeding studies with pure FB1
in American Institute of Nutrition-76 diets
indicate that the NOEL for elevation of uri-
nary free sphinganine in Sprague-Dawley rats
is 1 ppm (55). Once elevated by feeding an
apparently nephrotoxic concentration of FB1,
an apparently non-nephrotoxic concentration
(1 ppm) will keep the free sphinganine
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concentration at a level approaching that of
the nephrotoxic fumonisin dosage (10 ppm)
(55). Nonetheless, the elevation in free sphin-
goid bases and the associated fumonisin-
induced toxicities are reversible (94). 
Alterations in Complex Sphingolipids
Inhibition of sphinganine (sphingosine)
N-acyltransferase (CER synthase) in cells also
leads to a concentration-dependent reduction
in more complex sphingolipids (41,53), with
sphingomyelin biosynthesis being inhibited
earlier and at lower fumonisin concentrations
than glycosphingolipid biosynthesis (41).
There is no doubt that the loss of complex
sphingolipids also plays a role in the abnor-
mal behavior and altered morphology of
fumonisin-treated cells. For example, in the
LLC-PK1 renal cells, the morphologic
changes such as decreased cell–cell contact
and increased fibroblast-like appearance are
not reversed using ISP-Is, suggesting that
they are due to depletion of more complex
sphingolipids (67) or other factors. 
Glycosphingolipid changes also modulate
apoptosis. For example, fumonisin inhibition
of glycosphingolipid biosynthesis will protect
cells from the death induced by Shiga-like
toxins (SLT) in combination with butyric
acid, which sensitizes cells to SLT-induced
apoptosis (78). SLT (B subunit) ligation of
globoside Gb3 has been shown to induce
apoptosis (95). Recent studies have shown
that endotoxin and cytokines can increase
serine palmitoyltransferase activity (96), a
process that can sensitize cells to de novo
CER- or sphingoid base-induced cell death.
In LLC-PK1 renal epithelial cells, treatment
with SLT and endotoxin-containing bacterial
lysates had little effect on cell viability in the
absence of the proinflammatory cytokine,
TNF-α (Figure 6). However, cell death was
increased markedly in cultures treated with
the bacterial lysates when followed by TNF-
α and this increased cell death is prevented
by FB1 and/or ISP-I (Figure 6). Thus,
fumonisin inhibition of de novo sphin-
golipids biosynthesis in vivo could alter the
proapoptotic signals mediated by as yet
unidentified endogenous ligands for sphin-
golipid receptors. Fumonisins could also pro-
tect cells from the apoptosis associated with
microbial toxins and the sensitization
induced by cytokines or other factors that
stimulate de novo sphingolipid biosynthesis. 
Decreased CER Biosynthesis 
The inhibition of CER biosynthesis necessarily
precedes any change in the intracellular con-
centration of intermediates or end products
in the sphingolipid biosynthetic process.
Because increased CER concentration is an
important signal in the induction of cell
death, the inhibition of CER synthase by
fumonisins can inhibit cell death induced by
CER in short-term experiments, whereas
prolonged inhibition will promote free sphin-
goid base-induced cell death if free sphingoid
bases accumulate to toxic concentrations.
Fumonisin inhibition of CER synthesis may
also regulate numerous other critical cell reg-
ulatory functions that lead to altered prolifer-
ation and cell death. For example, FB1
protects cells from stress-induced apoptosis
that is mediated by increased de novo CER
biosynthesis: 
• Sphingosine-induced germinal vesicle
breakdown and oocyte maturation (98) 
• Apoptosis induced by pharmacologic
agents (99–103)
• Carnitine palmitoyltransferase inhibition-
induced apoptosis (104)
• Lipopolysaccharide/platelet-activating
factor-induced arachidonic acid release
(105)
• Chemical hypoxia-induced cell death (106)
• CD95 antigen-transduced, caspase-
dependent T-cell proliferation (107)
• Serum-stimulated retinoblastoma protein
dephosphorylation and cell cycle progres-
sion (108) 
• Multidrug resistance modulator-dependent
cytotoxicity (109)
• TNF-α/cycloheximide-induced endo-
thelial cell death (110)
• 12-O-tetradecanoylphorbol-13-acetate-
induced apoptosis (111)
• Fatty acid-induced nitric oxide synthase-
dependent apoptosis (112)
• Ionizing radiation-induced DNA damage
and cell death (113).
The ability of fumonisin inhibition of
CER biosynthesis to protect cells is of consid-
erable interest because primary rat hepatocyte
necrotic cell death is mediated by CER (but
not dihydroceramide) mitochondrial dysfunc-
tion (114), and dihydroceramide desaturase
activity depends on the redox state of the cell
(115). The ability of fumonisins to protect
oxidant-damaged cells from CER-mediated
apoptosis could also result in an accumula-
tion of cells with damaged DNA. 
Many of the processes that stimulate apop-
tosis via increased de novo CER biosynthesis
appear to be caused by increased serine
palmitoyltransferase activity. Ideally, speciﬁc
inhibitors of serine palmitoyltransferase and
inhibitors of CER synthase should be used in
combination to test the hypothesis that de
novo CER biosynthesis modulates cell func-
tion (54). The reason for this is that fumon-
isin inhibition of CER synthase causes
changes in many lipid metabolites (Figure 4)
that are known modulators of cellular regula-
tion, including both inducers of cell death and
promoters of cell survival. Use of serine palmi-
toyltransferase inhibitors in combination with
CER synthase inhibitors will block all de novo
fatty acyl CoA-dependent sphingolipid
biosynthesis and CER biosynthesis that use
free sphingoid bases derived from sphingolipid
turnover or dietary sources. Nonetheless, use
of fumonisins alone has revealed a great deal
about the processes that are controlled by de
novo sphingolipid biosynthetic pathways and
thus reveals the potential of fumonisin to per-
turb cellular regulation. Speciﬁc inhibitors of
serine palmitoyltransferase (myriocin) are
commercially available, as are inhibitors of
CER synthase (fumonisins).
Added to these sphingolipid-mediated
effects is the likelihood that fumonisins tar-
get other processes that can also contribute
to the observed cellular deregulation and
increased cancer risk in rodent liver and kid-
ney. In addition, other factors independent
of fumonisins (diet, immune status, infec-
tious agents, other toxins) can contribute to
increased cancer risk. Although the in vivo
evidence for most of these other proposed
targets is currently only weakly supported,
the evidence for fumonisin-induced disrup-
tion of sphingolipid metabolism in target tis-
sues has been demonstrated repeatedly in
many independent studies. 
Possible Mechanism of Cancer
Induction 
Theoretically, at any speciﬁc time the balance
between the intracellular concentration of
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Figure 6. An example of how FB1 can protect cells from
cell death induced by treatments that require de novo
sphingolipid biosynthesis as a critical step in the onset
of toxicity (97). Confluent (24 well plates, 2 cm2/well)
LLC-PK1 renal epithelial cells treated with phosphate-
buffered saline vehicle (control), 20 ng/mL of a lysate of
Shiga toxin–producing bacteria (SLT-lysate; Toxin
Technologies, Inc., Sarasota, FL), SLT-lysate plus 150
µM FB1 (+FB1), or SLT-lysate plus FB1 and ISP-I (450 nM)
for 20 hr followed by addition of 10 ng/mL of TNF-α
(+TNF) and additional incubation for 72 hr, and similar
treatments without addition of TNF-α (-TNF). Neither
the FB1 or ISP-I alone caused any detachment of cells
greater than the vehicle controls. Cell detachment was
determined as described in Riley et al. (67). Values are
means ± SD, n = 2 from one representative experiment.
ISP-I alone also prevents the cytotoxicity of SLT-lysates
plus TNF (data not shown).
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sphingolipid effectors that protect cells from
apoptosis (decreased CER, increased SPP)
and the concentration of effectors that induce
apoptosis (increased CER, free sphingoid
bases, fatty acids, or specific glycosphin-
golipids) will determine the observed cellular
response (Figure 3). In vitro, the response of
different cell lines to fumonisin-induced dis-
ruption of sphingolipid metabolism is diffi-
cult to predict. Some cell lines responded to
inhibition of CER synthase with increased
apoptosis and decreased proliferation (23,39,
53,56,65), whereas in other cell lines inhibi-
tion of CER synthase increases proliferation
(68) or has no effect on cell proliferation
(23). In addition, CER synthase inhibition
prevents the apoptotic effects of certain treat-
ments. Thus, the effects of disrupted sphin-
golipid metabolism are cell type and
treatment dependent. It has been proposed
that for nongenotoxic (not DNA reactive)
carcinogens, the balance between the rates of
apoptosis and proliferation are critical deter-
minants in tumorigenesis (116,117). Thus, in
affected tissues cells sensitive to the prolifera-
tive effect of decreased CER and increased
SPP (36) should be selected to survive and
proliferate when the conditions under which
the cells are exposed to fumonisins are such
that increased free sphingoid base concentra-
tion does not inhibit growth. Conversely,
when the rate of increase in free sphingoid
bases exceeds a cell’s ability to convert sphin-
ganine/sphingosine to dihydroceramide/CER
or their sphingoid base 1-phosphate, then free
sphingoid bases will accumulate. In this latter
case, cells sensitive to sphingoid base-induced
growth arrest will cease growing, and insensi-
tive cells will survive. In either case, if the
cells selected to die are not DNA-damaged
cells and the cells selected to survive are DNA
damaged, then the relative abundance of the
DNA-damaged cells will increase. The cancer
risk will also increase because the probability
of a transformed cell’s surviving will have
increased. In this theory, fumonisin acts to
increase the population of cells that have pre-
existing DNA defects, and fumonisin is not
itself DNA reactive. How these cells become
DNA damaged is irrelevant if the end result is
to increase their chance of survival. Another
condition that could alter the balance
between cell death and survival would be if
the block on CER synthase were reduced or
CER synthase expression were increased
while free sphinganine levels were still quite
high. In such a case, CER levels might
increase rapidly to toxic levels. Similar results
could occur with induction of serine palmi-
toyltransferase (increasing free sphinganine, as
seen in rapidly dividing cells) or inhibition of
enzymes in the degradative pathway. Several
studies have shown that fumonisin inhibits
de novo CER production and apoptosis
resulting from treatments that induce stress
sufficient to cause DNA damage (104,
106,113). Again, if DNA-damaged cells sur-
vive, one can imagine an increase in the pop-
ulation of DNA-damaged cells and an
increased cancer risk. 
In conclusion, we hypothesize that FB1-
induced alterations in sphingolipid signaling
pathways will lead to altered rates of cell death
and regeneration. In certain situations, CER
synthase-inhibited cells that are DNA dam-
aged may survive under conditions that would
normally lead to their death from CER gener-
ated de novo. Conversely, CER synthase inhi-
bition can lead to the accumulation of
sphingoid bases and their metabolites, which
would also alter rates of cell death and prolif-
eration. Given the current lack of evidence for
the DNA reactivity of fumonisins, the car-
cinogenic risk from fumonisin may a) be
related to its ability to increase the chance of
survival of cells that have been DNA damaged
by other means; b) stimulate cell division
directly (via SPP); c) increase regeneration in
response to increased cell death (via sphingoid
bases or depletion of more complex sphin-
golipids); or d) increase the chances of sur-
vival of preexisting DNA-damaged cells
through an insensitivity to the apoptotic
effects of disrupted sphingolipid metabolism. 
REFERENCES AND NOTES
1.  Wang E, Ross PF, Wilson TM, Riley RT, Merrill AH Jr. Increases
in serum sphingosine and sphinganine and decreases in com-
plex sphingolipids in ponies given feed containing fumonisins,
myocotoxins produced by Fusarium moniliforme. J Nutr 122:
1706–1716 (1992).
2.  Riley RT, Showker JL, Owens DL, Ross PF. Disruption of sphin-
golipid metabolism and induction of equine leucoencephaloma-
lacia by Fusarium proliferatum culture material containing
fumonisin B2 or B3. Environ Toxicol Pharmacol 3:221–228 (1997).
3.  Riley RT, An NH, Showker JL, Yoo H-S, Norred WP,
Chamberlain WJ, Wang E, Merrill AH Jr, Motelin G, Beasley
VR, et al. Alteration of tissue and serum sphinganine to
sphingosine ratio: an early biomarker of exposure to fumon-
isin-containing feeds in pigs. Toxicol Appl Pharmacol
118:105–112 (1993).
4.  Haschek WM, Gumprecht LA, Smith GW, Parker HM, Beasley
VR, Tumbleson ME. Effects of fumonisins in swine. In:
Advances in Swine Biomedical Research (Tumbleson ME,
Schook A, eds). New York:Plenum Press, 1996;99–112.
5.  Rotter BA, Thompson BK, Prelusky DB, Trenholm HL, Stewart B,
Miller JD, Savard ME. Response of growing swine to pure
dietary fumonisin B1 during an 8 week period: growth and clini-
cal parameters. Nat Toxins 4:42–50 (1996).
6.  Gumprecht LA, Beasley VR, Weigel RM, Parker HM, Tumbleson
ME, Bacon CW, Meredith FI, Haschek WM. Development of
fumonisin-induced hepatotoxicity and pulmonary edema in
orally dosed swine: morphological and biochemical alterations.
Toxicol Pathol 26:777–788 (1998).
7.  Riley RT, Hinton DM, Chamberlain WJ, Bacon CW, Wang E,
Merrill AH Jr, Voss KA. Dietary fumonisin B1 induces disruption
of sphingolipid metabolism in Sprague-Dawley rats: a new
mechanism of nephrotoxicity. J Nutr 124:594–603 (1994).
8.  Gelderblom WCA, Smuts CM, Abel S, Snyman SD, Cawood MA,
Van der Westhuizen L, Huber WW, Swanevelder S. Effect of
fumonisin B1 on the levels and fatty acid composition of
selected lipids in rat liver, in vivo. Food Chem Toxicol 35:
647–656 (1997).
9.  Gelderblom WCA, Snyman SD, Lebepe-Mazur S, Van der
Westhuizen L, Kriek NPJ, Marasas WFO. The cancer-promoting
potential of fumonisin B1 in rat liver using diethylnitrosamine as
a cancer initiator. Cancer Lett 109:101–108 (1996).
10.  Voss KA, Riley RT, Bacon CW, Meredith FI, Norred WP. Toxicity
and sphinganine levels are correlated in rats fed fumonisin B1
(FB1) or hydrolyzed FB1. Environ Toxicol Pharmacol 5:101–104
(1998).
11. de  Nijs M. Public Health Aspects of Fusarium Mycotoxins in
Food in The Netherlands: A Risk Assessment [PhD thesis].
Wageningen, The Netherlands:Wageningen Agricultural
University, 1998. 
12.  NTP. Toxicology and Carcinogenesis Studies of Fumonisin B1
(CAS No. 116355-83-0) in F344/N rats and B6C3F1 mice (Feed
studies). Draft Technical Report NTP TR-496 (NIH Pub No 99-
3955). Research Triangle Park, NC:National Toxicology Program,
1999.
13.  Tsunoda M, Sharma RP, Riley RT. Early fumonisin B1 toxicity in
relation to disrupted sphingolipid metabolism in male BALB/c
mice. J Biochem Mol Toxicol 12:281–289 (1998).
14. Sharma RP, Bhandari N, Riley RT, Voss KA, Meredith FI.
Tolerance to fumonisin toxicity in a mouse strain lacking the P75
tumor necrosis factor receptor. Toxicology 143:183–194 (2000).
15.  Sharma RP, Bhandari N, Tsunoda M, Riley RT, Voss KA.
Fumonisin hepatotoxicity is reduced in mice carrying the human
tumor necrosis factor α transgene. Arch Toxicol 74:238–248
(2000).
16.  Sharma RP, Bhandari N, Tsunoda M, Riley RT, Voss KA,
Meredith FI. Fumonisin toxicity in a trangenic mouse model
lacking the mdr1a/1b P-glycoprotein genes. Environ Toxicol
Pharmacol 8:173–182 (2000). 
17.  Riley RT, Showker JL, Voss KA, Enongene EN, Meredith FI,
Sharma RP. Fumonisin B1-induced liver toxicity, liver free sphin-
ganine and lipid peroxidation compared in six different strains
of male mice. Toxicol Sci 54:307 (2000).
18.  Huang C, Dickman M, Henderson G, Jones C. Repression of pro-
tein kinase C and stimulation of cyclic AMP response elements
by fumonisin, a fungal encoded toxin which is a carcinogen.
Cancer Res 55:1655–1659 (1995).
19.  Yeung JM, Wang H-Y, Prelusky DB. Fumonisin B1 induces pro-
tein kinase C translocation via direct interaction with diacylglyc-
erol binding site. Toxicol Appl Pharmacol 141:178–184 (1996). 
20.  Wattenberg EV, Badria FA, Shier WT. Activation of mitogen-
activated protein kinase by the carcinogenic mycotoxin fumon-
isin B1. Biochem Biophys Res Commun 227: 622–627 (1996).
21.  Fukuda H, Shima H, Vesonder RF, Tokuda H, Nishino H, Katoh S,
Tamura S, Sugimura T, Nagao M. Inhibition of serine threonine
phosphatases by fumonisin B1, a mycotoxin. Biochem Biophys
Res Commun 220:160–165 (1996).
22.  Ramljak D, Calvert RJ, Wiesenfeld PW, Diwan BA, Catipovic B,
Marasas WFO, Victor TC, Anderson LM, Gelderblom WCA. A
potential mechanism for fumonisin B1-mediated hepatocarcino-
genesis: cyclin D1 stabilization associated with activation of
Akt and inhibition of GSK-3beta activity. Carcinogenesis
21:1537–1546 (2000).
23.  Ciacci-Zanella JR, Merrill AH Jr, Wang E, Jones C.
Characterization of cell cycle arrest by fumonisin B1 in CV-1
cells. Food Chem Toxicol 36:791–804 (1998).
24.  Lemmer ER, Hall PM, Omori N, Shephard EG, Gelderblom WCA,
Cruse JP, Barnard RA, Marasas WFO, Kirsch RE, Thorgeirsson
SS. Histopathology and gene expression changes in rat liver
during feeding of fumonisin B1, a carcinogenic mycotoxin pro-
duced by Fusarium moniliforme. Carcinogenesis 20:817–824
(1999).
25.  Ciacci-Zanella J, Jones C. Fumonisin B1, a mycotoxin contami-
nant of cereal grains, and inducer of apoptosis via tumor necro-
sis factor pathway and caspase activation. Food Chem Toxicol
37:703–712 (1999).
26.  Dugyala RP, Sharma RP, Tsunoda M, Riley RT. Tumor necrosis
factor as a contributor in fumonisin B1-toxicity. J Pharmacol Exp
Ther 285:317–324 (1998).
27.  Sauviat MP, Laurent D, Kohler F, Pellegrin F. Fumonisin, a toxin
from the fungus Fusarium moniliforme Sheld, blocks both the
calcium current and the mechanical activity in frog atrial mus-
cle. Toxicon 29:1025–1031 (1991).
28.  Lim CW, Parker HM, Vesonder RF, Haschek WM. Intravenous
fumonisin B1 induces cell proliferation and apoptosis in the rat.
Nat Toxins 4:34–41 (1996).
29.  Kang YK, Alexander JM. Alteration of the glutathione redox
cycle status in fumonisin B1-treated pig kidney cells. J Biochem
Toxicol 11:121–126 (1997).
30.  Gelderblom WCA, Smuts CM, Snyman SD, Cawood MA, van
der Westhuizen L, Swanevelder S. Effect of fumonisin B1 on
protein and lipid synthesis in primary rat hepatocytes. Food
Chem Toxicol 34:361–369 (1996).
31.  Yin J-J, Smith MJ, Eppley RM, Page SW, Sphon JA. Effects of
fumonisin B1 on lipid peroxidation in membranes. Biochim
Biophys Acta 1371:134–142 (1998).
109S2.Part 2  04/16/01  5:55 PM  Page 306    (Black plate)Fumonisins disrupt sphingolipid metabolism
32.  Abado-Becognee K, Mobio TA, Ennamany R, Fleurat-Lessard F,
Sheir WT, Badria F, Creppy EE. Cytotoxicity of fumonisin
B1:implication of lipid peroxidation and inhibition of protein and
DNA syntheses. Arch Toxicol 72:233–236 (1998). 
33.  Abel S, Gelderblom WCA. Oxidative damage and fumonisin B1-
induced toxicity in primary rat hepatocytes and rat liver in vivo.
Toxicology 131:121–131 (1998).
34.  Rotter BA, Oh Y-N. Mycotoxin fumonisin B1 stimulates nitric
oxide production in a murine macrophage cell line. Nat Toxins
4:291–294 (1996).
35.  Hannun YA, Luberto C. Ceramide in the eukaryotic stress
response. Trends Cell Biol 10(2):73–80 (2000).
36.  Spiegel S. Sphingosine 1-phosphate: a prototype of a new class
of second messenger. J Leukoc Biol 65:341–344 (1999).
37.  Kolesnick RN, Krönke M. Regulation of ceramide production
and apoptosis. Annu Rev Physiol 60:643–665 (1998).
38.  Wang E, Norred WP, Bacon CW, Riley RT, Merrill AH Jr.
Inhibition of sphingolipid biosynthesis by fumonisins: implica-
tions for diseases associated with Fusarium moniliforme. J Biol
Chem 266:14486–14490 (1991).
39.  Yoo H-S, Norred WP, Showker JL, Riley RT. Elevated sphingoid
bases and complex sphingolipid depletion as contributing fac-
tors in fumonisin-induced cytotoxicity. Toxicol Appl Pharmacol
138:211–218 (1996).
40.  Merrill AH Jr, Wang E, Gilchrist DG, Riley RT. Fumonisins and
other inhibitors of de novo sphingolipid biosynthesis. In:
Advances in Lipid Research: Sphingolipids and Their
Metabolites, Vol 26 (Bell RM, Hannun YA, Merrill AH Jr, eds).
Orlando, FL:Academic Press, 1993;215–234. 
41.  Merrill AH Jr, van Echten G, Wang E, Sandhoff K. Fumonisin B1
inhibits sphingosine (sphinganine) N-acyltransferase and de
novo sphingolipid biosynthesis in cultured neurons in situ. J
Biol Chem 268:27299–27306 (1993).
42.  Merrill AH Jr, Wang E, Vales TR, Smith ER, Schroeder JJ,
Menaldino DS, Alexander C, Crane HM, Xia J, Liotta DC, et al.
Fumonisin: toxicity and sphingolipid biosynthesis. Adv Exp Med
Biol 392: 297–306 (1996). 
43.  Norred WP, Plattner RD, Dombrink-Kurtzman MA, Meredith FI,
Riley RT. Mycotoxin-induced elevation of free sphingoid bases
in precision-cut rat liver slices: speciﬁcity of the response and
structure-activity relationships. Toxicol Appl Pharmacol 147:
63–70 (1997).
44.  van der Westhuizen L, Shephard GS, Synman SD, Abel S,
Swanevelder S, Gelderblom WCA. Inhibition of sphingolipid
biosynthesis in rat primary hepatocyte cultures by fumonisin B1
and other structurally related compounds. Food Chem Toxicol
36:497–503 (1998).
45.  Plattner RD. Personal communication.
46.  Humpf H-U, Smelz EM, Meredith FI, Merrill AH. Acylation of
naturally occurring and synthetic 1-deoxysphinganines. J Biol
Chem 273:19060–19064 (1998).
47.  Merrill AH Jr, Liotta DC, Riley RT. Bioactive properties of sphin-
gosine and structurally related compounds. In: Handbook of
Lipid Research, Vol 8, Lipid Second Messengers (Bell RM, ed).
New York:Plenum Press, 1996;205–237.
48.  Ledeen RW, Hakomori S, Yates AJ, Schneider JS, Yu RK, eds.
Sphingolipids as Signaling Molecules in the Nervous System.
Ann NY Acad Sci, Vol 845. New York:The New York Academy
of Sciences, 1998.
49.  Riley RT, Voss KA, Norred WP, Sharma RP, Wang E, Merrill AH.
Fumonisins: mechanism of mycotoxicity. Rev Méd Vét
149:617–626 (1998).
50.  Enongene EN, Sharma RP, Bhandari N, Voss KA, Riley RT.
Disruption of sphingolipid metabolism in small intestines, liver
and kidney of mice dosed subcutaneously with fumonsin B1.
Food Chem Toxicol 38:793–799 (2000).
51.  Enongene EN, Sharma RP, Voss KA, Riley RT. Comparison of
sphingolipid changes in two strains of mice dosed with fumon-
isin B1 by two different routes. Toxicol Sci 54:142 (2000). 
52.  Riley RT, Meredith FI. Unpublished data.
53.  Yoo H-S, Norred WP, Wang E, Merrill AH Jr, Riley RT.
Fumonisin inhibition of de novo sphingolipid biosynthesis and
cytotoxicity are correlated in LLC-PK1 cells. Toxicol Appl
Pharmacol 114:9–15 (1992).
54.  Riley RT, Plattner RD. Fermentation, partial puriﬁcation, use of
serine palmitoyltransferase inhibitors from Isaria (=Cordyceps)
sinclairii. Methods Enzymol 311:348–360 (2000).
55.  Wang E, Riley RT, Meredith FI, Merrill AH Jr. Time course,
dose-dependence, and reversibility of increases in urinary
sphinganine and sphingosine in animals fed deﬁned diets con-
taining fumonisin B1: characteristics of urinary biomarkers for
exposure to fumonisin(s). J Nutr 129:214–220 (1999).
56.  Schmelz E-M, Dombrink-Kurtzman MA, Roberts PC, Kozutsumi
Y, Kawasaki T, Merrill AH Jr. Induction of apoptosis by fumon-
isin B1 in HT29 cells is mediated by the accumulation of
endogenous free sphingoid bases. Toxicol Appl Pharmacol 148:
252–260 (1998).
57.  Li Wu, Riley RT, Voss KA, Norred WP. Role of proliferation in
the toxicity of fumonisin B1: enhanced hepatotoxic response in
partially hepatectomized rat. J Toxicol Environ Health 60:
441–457 (2000).
58.  Badiani K, Byers DM, Cook HW, Ridgway ND. Effect of fumon-
isin B1 on phosphatidylethanolamine biosynthesis in Chinese
hamster ovary cells. Biochim Biophys Acta 1304:190–196
(1996).
59. Smith ER, Merrill AH Jr. Differential roles of de novo sphin-
golipid biosynthesis and turnover in the “burst” of free sphingo-
sine and sphinganine, and their 1-phosphates and
N-acyl-derivatives, that occurs upon changing the medium of
cells in culture. J Biol Chem 270:18749–18758 (1995).
60.  Merrill AH Jr. Characterization of serine palmitoyltransferase
activity in Chinese hamster ovary cells. Biochim Biophys Acta
754:284–291 (1983).
61.  Stevens VL, Nimkar S, Jamison WC, Liotta DC, Merrill AH Jr.
Characteristics of the growth inhibition and cytotoxicity of long-
chain (sphingoid) bases for Chinese hamster ovary cells: evi-
dence for an involvement of protein kinase C. Biochim Biophys
Acta 1051:37–45 (1990).
62.  Sweeney EA, Sakakura C, Shirahama T, Masamune A, Ohta H,
Hakomori S-I, Igarashi Y. Sphingosine and methylated deriva-
tive N,N-methylsphingosine (DMS) induce apoptosis in a variety
of human cancer cell lines. Int J Cancer 66:358–366 (1996).
63.  Nakamura S, Kozutsumi Y, Sun Y, Miyake Y, Fujita T, Kawasaki
T. Dual role of sphingolipids in signaling of the escape from and
onset of apoptosis in a mouse cytotoxic T-cell line, CTLL-2. J
Biol Chem 271:1255–1257 (1996).
64.  Riboni L, Prinetti A, Bassi R, Viani P, and Tettamanti G. The
effects of exogenous sphingosine on Neuro2a cells are strictly
related to the overall capacity of cells to metabolize sphingo-
sine. J Biochem 124:900–904 (1998).
65.  Tolleson WH, Couch LH, Melchior WB Jr, Jenkins GR,
Muskhelishvili M, Muskhelishvili L, McGarrity LJ, Domon OE,
Morris SM, Howard PC. Fumonisin B1 induces apoptosis in cul-
tured human keratinocytes through sphinganine accumulation
and ceramide depletion. Int J Oncol 14:833–843 (1999).
66.  Isogai C, Murate T, Tamiya-Koizumi K, Yoshida S, Ito T, Nagai
H, Kinoshita T, Kagami Y, Hotta T, Hamaguchi M, et al. Analysis
of bax protein in sphingosine-induced apoptosis in the human
leukemic cell line TF1 and its bcl-2 transfectants. Exp Hematol
26:1118–1125 (1998).
67.  Riley RT, Voss KA, Norred WP, Bacon CW, Meredith FI, Sharma
RP. Serine palmitoyltransferase inhibition reverses antiprolifera-
tive effects of ceramide synthase inhibition in cultured renal
cells and suppresses free sphingoid base accumulation in kidney
of BALBc mice. Environ Toxicol Pharmacol 7:109–118 (1999).
68.  Schroeder JJ, Crane HM, Xia J, Liotta DC, Merrill AH Jr.
Disruption of sphingolipid metabolism and stimulation of DNA
synthesis by fumonisin B1. A molecular mechanism for carcino-
genesis associated with Fusarium moniliforme. J Biol Chem
269:3475–3481 (1994).
69.  Ramasamy S, Wang E, Hennig B, Merrill AH Jr. Fumonisin B1
alters sphingolipid metabolism and disrupts the barrier function
of endothelial cells in culture. Toxicol Appl Pharmacol 133:
343–348 (1995).
70.  Smith ER, Jones PL, Boss JM, Merrill AH Jr. Changing J774A.1
cells to new medium perturbs multiple signaling pathways,
including the modulation of protein kinase C by endogenous
sphingoid bases. J Biol Chem 272:5640–5646 (1997).
71.  Harel R, Futerman AH. Inhibition of sphingolipid synthesis
affects axonal outgrowth in cultured hippocampal neurons. J
Biol Chem 268:14476–14481 (1993).
72.  Schwarz A, Rapaport E, Hirschberg K, Futerman H. A regulatory
role for sphingolipids in neuronal growth. J Biol Chem 270:
10990–10998 (1995).
73.  Meivar-Levy I, Sabanay H, Bershadsky AD, Futerman AH. The
role of sphingolipids in the maintenance of ﬁbroblast morphol-
ogy. J Biol Chem 272:1558–1564 (1997).
74.  Hidari Jwa KIP, Ichikawa S, Fujita T, Sakiyama H, Hirabayashi
Y. Complete removal of sphingolipids from the plasma mem-
brane disrupts cell to substratum adhesion of mouse melanoma
cells. J Biol Chem 271:14636–14641 (1996).
75.  Hanada K, Izawa K, Nishijima M, Akamatsu Y. Sphingolipid
deficiency induces hypersensitivity of CD14, glycosyl phos-
phatidylinositol-anchored protein to phosphatidylinositol spe-
ciﬁc phospholipase C. J Biol Chem 268:13820–13823 (1993).
76.  Stevens VL, Tang J. Fumonisin B1-induced sphingolipid deple-
tion inhibits uptake via the glycosylphosphatidylinositol-
anchored folate receptor. J Biol Chem 272:18020–18025 (1997).
77.  Gillard BK, Harrell RG, Marcus DM. Pathways of glycosphin-
golipid biosynthesis in SW13 cells in the presence and absence
of vimentin intermediate ﬁlaments. Glycobiology 6:33–42 (1996).
78.  Sandvig K, Garred O, van Helvoort A, van Meer G, van Deurs B.
Importance of glycolipid synthesis for butyric acid-induced sen-
sitization to Shiga toxin and intracellular sorting of toxin in
A431 cells. Mol Biol Cell 7:1391–1404 (1996). 
79.  Roccamo AM, Pediconi MF, Aztiria E, Zanello L, Wolstenholme
A, Barrantes FJ. Cells defective in sphingolipid biosynthesis
express low amounts of muscle nicotinic acethylcholine recep-
tor. Eur J Neurosci 11:1615–1623 (1999).
80.  Lavie Y, Cao H-T, Bursten SL, Guiliano AE, Cabot MC.
Accumulation of glucosylceramides in multidrug-resistant
cancer cells. J Biol Chem 271:19530–19536 (1996).
81.  Boldin S, Futerman AH. Glucosylceramide synthesis is required
for basic fibroblast growth factor and laminin to stimulate
axonal growth. J Neurochem 68:882–885 (1997).
82.  Zacharias C, van Echten-Deckert G, Wang E, Merrill AH Jr,
Sandoff K. The effect of fumonisin B1 on developing chick
embryos: correlation between de novo sphingolipid biosynthe-
sis and gross morphological changes. Glycoconj J 13:167–175
(1996).
83.  Riley RT, Wang E, Merrill AH Jr. Liquid chromatographic deter-
mination of sphinganine and sphingosine: use of the free sphin-
ganine-to-sphingosine ratio as a biomarker for consumption of
fumonisins. J AOAC Int 77:533–540 (1994).
84.  Merrill AH Jr, Schmelz E-M, Dillehay DL, Spiegel S, Shayman
JA, Schroeder JJ, Riley RT, Voss KA, Wang E. Sphingolipids-
the enigmatic lipid class: biochemistry, physiology, and patho-
physiology. Toxicol Appl Pharmacol 142:208–225 (1997).
85.  Futerman AH. Inhibition of sphingolipid synthesis: effects on
glycosphingolipid-GPI-anchored protein microdomains. Trends
Cell Biol 5:377–380 (1995).
86.  Yates AJ, Rampersaud A. Sphingolipids as receptor modulators,
an overview. Ann NY Acad Sci 845:57–71 (1998).
87.  Radin NS. Chemotherapy by slowing glucosphingolipid synthe-
sis. Biochem Pharmacol 57:589–595 (1999).
88.  Hanada K, Nishijima M, Kiso H Jr, Hasegawa A, Fujita S, Ogawa
T, Akamatsu Y. Sphingolipids are essential for the growth of
Chinese hamster ovary cells. Restoration of the growth of a
mutant defective in sphingoid base biosynthesis with exogenous
sphingolipids. J Biol Chem 267:23527–23533 (1992).
89.  LaBorde JB, Terry KK, Howard PC, Chen JJ, Collins TFX,
Shackelford ME, Hansen DK. Lack of embryotoxicity of fumon-
isin B1 in New Zealand white rabbits. Fundam Appl Toxicol
40:120–128 (1997).
90.  Carlson DB, Williams DE, Spitsbergen JM, Ross PF, Bacon CW,
Meredith FI, Riley RT. Fumonisin B1 promotes aflatoxin B1 and
N-methyl-N’-nitro-nitrosoguanidine initiated liver tumors in
rainbow trout. Toxicol Appl Pharmacol (in press 2001). 
91.  Meredith FI, Riley RT, Bacon CW, Williams DE, Carlson D.
Extraction, quantiﬁcation, and biological activity of fumonisin B1
incorporated into Oregon Test Diet and fed to rainbow trout. J
Food Prot 61:1034–1038 (1998).
92.  Voss KA, Chamberlain WJ, Bacon CW, Herbert RA, Walters DB,
Norred WP. Subchronic feeding study of the mycotoxin fumon-
isin B1 in B6C3F1 mice and Fischer 344 rats. Fundam Appl
Toxicol 24:102–110 (1995).
93.  Gumprecht LA, Marcucci A, Vesonder RF, Riley RT, Showker JL,
Beasley VR, Haschek WM. Effects of intravenous fumonisin B1
in rabbits: nephrotoxicity and sphingolipid alterations. Nat
Toxins 3:395–403 (1995).
94.  Voss KA, Plattner RD, Riley RT, Meredith FI, Norred WP. In vivo
effects of fumonisin B1-producing and fumonisin B1-nonproduc-
ing Fusarium moniliforme isolates are similar: fumonisins B1
and B3 cause hepato- and nephrotoxicity in rats.
Mycopathologia 141:45–58 (1998).
95.  Arab S, Murakami M, Dirks P, Boyd B, Hubbard SL, Lingwood
CA, Rutka JT. Verotoxins inhibit the growth of and induce apop-
tosis in human astrocytoma cells. J Neurooncol 40:137–150
(1998).
96.  Memon RA, Holleran WM, Moser AH, Seki T, Uchida Y, Fuller
J, Shigenaga JK, Grunfeld C, Feingold KR. Endotoxin and
cytokines increase hepatic sphingolipid biosynthesis and pro-
duce lipoproteins enriched in ceramides and sphingomyelin.
Arterioscler Thromb Vasc Biol 18:1257–1265 (1998). 
97.  Riley RT, Showker JL. Unpublished data.
98.  Strum JC, Swenson KI, Turner JE, Bell RM. Ceramide triggers
meiotic cell cycle progression in Xenopus oocytes. J Biol Chem
270:13541–13547 (1995).
99.  Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z,
Kolesnick R. Ceramide synthase mediates daunorubicin-induced
apoptosis: an alternative mechanism for generating death sig-
nals. Cell 82:404–414 (1995).
Environmental Health Perspectives • VOLUME 109 | SUPPLEMENT 2 | May 2001 307
109S2.Part 2  04/16/01  5:55 PM  Page 307    (Black plate)Riley et al.
308 VOLUME 109 | SUPPLEMENT 2 | May 2001 • Environmental Health Perspectives
100. Witty JP, Bridgham JT, Johnson AL. Induction of apoptotic cell
death in hen granulosa cells by ceramide. Endocrinology 137:
5269–5277 (1996).
101.  Suzuki A, Iwasaki M, Kato M, Wagai N. Sequential operation of
ceramide synthesis and ICE cascade in CPT-11-initiated apop-
totic cell death. Exp Cell Res 233:41–47 (1997).
102. DiPietrantonio AM, Hsieh T-C, Olson SC, Wu JM. Regulation of
G1/S transition and induction of apoptosis in HL60 leukemia
cells by fenretinide (4HPR). Int J Cancer 78:53–61 (1998).
103. Wieder T, Orfanos CE, Geilen CC. Induction of ceramide-medi-
ated apoptosis by the anticancer phospholipid analog, hexade-
cylphosphocholine. J Biol Chem 273:11025–11031 (1998). 
104. Paumen MB, Ishida Y, Muramatsu M, Yamamoto M, Honjo T.
Inhibition of carnitine palmitoyltransferase I augments sphin-
golipids synthesis and palmitate-induced apoptosis. J Biol
Chem 272:3324–3329 (1997).
105. Balsinde J, Balboa MA, Dennis EA. Inflammatory activation of
arachidonic acid signaling in murine P388D1 macrophages via
sphingomyelin synthesis. J Biol Chem 272:20373–20377
(1997).
106.  Ueda N, Kaushal GP, Hong X, Shah SV. Role of enhanced
ceramide generation in DNA damage and cell death in chemical
hypoxic injury to LLC-PK1 cells. Kidney Int 54:399–406 (1998).
107. Sakata K-M, Sakata A, Vela-Roch N, Espinosa R, Escalante A,
Kong L, Nakabayashi T, Cheng J, Talal N, Dang H. Fas (CD95)-
transduced signal preferentially stimulates lupus peripheral T
lymphocytes. Eur J Immunol 28:2648–2660 (1998). 
108. Lee JY, Leonhardt LG, Obeid LM. Cell-cycle-dependent changes
in ceramide levels preceding retinoblastoma protein
dephoshorylation in G2/M. Biochem J 344:457–461 (1998). 
109.  Cabot MC, Han T-Y, Giuliano AE. The multidrug resistance mod-
ulator SDZ PSC 833 is a potent activator of ceramide formation.
FEBS Lett 431:185–188 (1998).
110. Xu J, Yeh C-H, Chen S, He L, Sensi SL, Canzoniero LMT, Choi
DW, Hsu CY. Involvement of de novo ceramide biosynthesis in
tumor necrosis factor-α/cycloheximide-induced cerebral
endothelial cell death. J Biol Chem 273:16521–16526 (1998).
111.  Garzotto M, White-Jones M, Jiang Y, Ehleiter D, Liao W-C,
Haimovitz-Friedman A, Fuks Z, Kolesnick R. 12-O-
Tetradenaoylphorbol-13-acetate-induced apoptosis in LNCaP
cells is mediated through ceramide synthase. Cancer Res
58:2260–2264 (1998).
112.  Shimabukuro M, Zhou Y-T, Levi M, Unger RH. Fatty acid-
induced B cell apoptosis: a link between obesity and diabetes.
Proc Natl Acad Sci USA 95:2498–2502 (1998).
113.  Liao W-C, Haimovitz-Friedman A, Persaud RS, McLaughlin M,
Ehleiter D, Zhang N, Gatei M, Lavin M, Kolesnick R, Fuks Z.
Ataxia telangiectasia-mutated gene product inhibits DNA dam-
age-induced apoptosis via ceramide synthase. J Biol Chem 274:
17908–17917 (1999). 
114.  Arora A, Jones BJ, Patel TC, Bronk SF, Gorres GJ. Ceramide
induces hepatocyte cell death through disruption of mitochondr-
ial function in the rat. Hepatology 25:958–963 (1997).
115. Michel C, van Echten-Deckert G, Rother J, Sandoff K, Wang E,
Merrill AH Jr. Characterization of ceramide synthesis. J Biol
Chem 272:22432–22437 (1997).
116. Cohen SM. Role of cell proliferation in regeneration and neo-
plastic disease. Toxicol Lett 82/83:15–21 (1995).
117.  Goldworthy TL, Conolly RB, Fransson-Steen R. Apoptosis and
cancer risk assessment. Mutat Res 365:71–90 (1996).
109S2.Part 2  04/16/01  5:55 PM  Page 308    (Black plate)